HYDERABAD: Hyderabad-based MSN Labs (MSN) on Thursday said it has entered into a royalty-free, non-exclusive, voluntary license agreement with US drug giant Eli Lilly & Co for manufacturing and marketing Covid-19 treatment drug Baricitinib in India.
MSN said it will be launching the product under the brand name Baridoz in two strengths 2 mg & 4mg.
The company has also developed the active pharmaceutical ingredient and the formulation of Baricitinib in its in-house R&D and manufacturing units, it said.
The rheumatoid arthritis drug Baricitinib has been granted a restricted emergency use approval in India by the Central Drugs Standard Control Organization (CDSCO) for emergency use in combination with Remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).